Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study
1Department of Orthopedics and Traumatology, Medical Faculty of Gazi University, Ankara, Turkey
2Department of Orthopaedics and Traumatology, Aksaray University Training and Research Hospital, Aksaray, Turkey
3Department of Orthopaedics and Traumatology, Lithuanian University of Health Sciences, Kaunas, Lithuania
4Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden
5Department of Biomedical Engineering, Lund University, Lund, Sweden
Keywords: Hip fracture, index, osteoporosis, risk factors, stratification
Objectives: This study aims to test the feasibility of the Fracture and Mortality Risk Evaluation (FAME) Index.
Patients and methods: Two academic centers in Lithuania and Turkey participated in this retrospective study conducted between November 2018 and July 2019. A total of 100 consecutive patients (22 males, 78 females; mean age 78.9 years; range, 45 to 100 years) with low energy proximal femur fractures admitted for surgery were included in the study. Fracture Risk Assessment tool (FRAX) and the Sernbo scores were calculated and patients were classified into one of the nine subcategories of the FAME Index.
Results: Demographics and FAME Index classifications were similar between centers. Patients with high risk of fracture and low risk of mortality accounted for 18% of all patients, which is the FAME Index subcategory to theoretically benefit from cancellous bone augmentation during internal fixation of a fragility hip fracture the most.
Conclusion: The FAME Index was successfully applied in clinical emergency setting utilizing a simple form, and demonstrated promising potential in stratification of hip fractures most suitable for screw and device augmentation. Larger studies with at least one-year of follow-up are warranted to verify the validity of FAME Index.
Citation: Sezgin EA, Markevičiūtė V, Širka A, Tarasevičius S, Raina DB, Isaksson H, et al. Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study. Jt Dis Relat Surg 2020;31(2):i-vi.
LL is a board member of Bone Support AB, Lund, Sweden and Ortho Cell, Australia. The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The financial support to the researchers was granted by VINNOVA innovation agency in Sweden (grant 2017–00269), VR-The Swedish Research Council (grant 2015–06717) and the Foundation for Disabled people in Scania, Sweden. The funding bodies had no role in the design of the study, data collection, analysis, and interpretation of data or in writing the manuscript.